- AuthorisedTherapeutic confirmatory (Phase III)
A multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients: efficacy and microbiologic safety.
This study compares two antibiotics, fosfomycin and ciprofloxacin, for treating fever in patients with blood cancers when their immune system is weak after chemotherapy. It aims to see which one works better and is safer for preventing serious infections.
For: Post-chemotherapy neutropenia with high risk of developing infection in patients with acute leukemia undergoing induction · autologous or allogeneic hematopoietic stem cell transplantation (HSCT).Spain - Active not recruitingNA
CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia)
This study, CiproPAL, looks at whether an antibiotic called ciprofloxacin can reduce infections in children aged 1-17 with a type of blood cancer called Acute Lymphoblastic Leukaemia (ALL). It compares daily ciprofloxacin to standard care during the early stages of their ALL treatment.
For: Acute Lymphoblastic Leukaemia - CategoryUnited Kingdom - Ongoing, recruitingTherapeutic confirmatory (Phase III)
COTRIVAP - Efficacy of cotrimoxazole as a de-escalation treatment of Ventilator-Associated Pneumonia in intensive care unit. Multicentric non-inferiority randomised controlled trial
This study is looking at whether a common antibiotic, co-trimoxazole, can be used to treat pneumonia in patients on a ventilator in intensive care. It compares it to standard treatments to see if it works just as well and is safe.
For: Intensive Care · Ventilator-associated PneumoniaFrance - AuthorisedTherapeutic use (Phase IV)
AIR. ANTIBIOTIC THERAPY IN RESPIRATORY TRACT INFECTIONS A controlled randomized, open label, multicenter, non-inferiority trial evaluating an individualized antibiotic treatment duration based on patient clinical response, evaluated through connected devices, for suspected community acquired pneumonia in the community setting
This study, called AIR, is looking at the best way to use antibiotics for chest infections (pneumonia). It compares different lengths of antibiotic treatment to see which works best, aiming to reduce how many antibiotics patients need.
For: Community acquired pneumonia (CAP)France - AuthorisedPhase I and Phase II (Integrated)- Other
Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System and verteporfin for injection for the treatment of primary localized prostate cancer
This study is testing a new way to treat prostate cancer that hasn't spread. It uses a special light treatment and a drug called Visudyne. Doctors want to see how safe it is and how well it works to remove cancer cells.
For: Primary localised prostate cancerGermany - AuthorisedTherapeutic confirmatory (Phase III)
Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the outpatient care of chemotherapy-induced fever in adult haematology patients. AC-CIF Protocol
This study looks at how well different antibiotic treatments work for adult cancer patients on chemotherapy who develop a fever. It compares two common antibiotic combinations to see which is better at getting rid of the fever without needing changes to treatment.
For: Adult patients treated for haematological disorders · in whom chemotherapy regimens are expected to induce neutropenia lasting <7 daysFrance - AuthorisedTherapeutic use (Phase IV)
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
This study looks at how well antibiotics work in very sick patients. Researchers want to make sure these important medicines reach the right levels in the body to fight serious infections effectively and safely. It's about getting the dose just right.
For: Serious infections in critically ill patients treated with antibioticsFrance - AuthorisedPhase III and phase IV (Integrated)
Prospective Multicenter Randomized Non-Inferiority Study Comparing 7 Days Versus 14 Days of Antibiotic Treatment for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)
This study compares different antibiotic treatment lengths (7 days vs. 14 days) for kidney transplant patients who get a kidney infection. Researchers want to see if a shorter treatment works just as well to prevent serious problems.
For: Graft pyelonephritis in kidney transplant recipientsSpain